Colitis and myocarditis were frequent causes of deaths from combination ICI therapy, whereas pneumonitis, hepatitis and neuro-toxicities most commonly contributed to anti-PD-1 or PD-L1 related fatalities11. This evidence concerns the gene PDCD1 and pneumonitis.